Search

Your search keyword '"localized aggressive lymphoma"' showing total 2 results
Start Over Descriptor "localized aggressive lymphoma"
2 results on '"localized aggressive lymphoma"'

1. Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?

Author

Patrizia Mondello, Salvatore Cuzzocrea, Michael Mian, Carmela Aloisi, and Vincenzo Pitini

Subjects
Pathology, medicine.medical_specialty, medicine.medical_treatment, BRITISH-COLUMBIA, Aggressive lymphoma, Antibodies, Monoclonal, Murine-Derived, immune system diseases, hemic and lymphatic diseases, MALIGNANT-LYMPHOMA, RADIATION-THERAPY, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, ONCOLOGY-GROUP, Radiology, Nuclear Medicine and imaging, Cyclophosphamide, neoplasms, ELDERLY-PATIENTS, PROGNOSTIC INDEX, CHOP PLUS RADIOTHERAPY, biology, medicine.diagnostic_test, business.industry, LOCALIZED AGGRESSIVE LYMPHOMA, NON-HODGKINS-LYMPHOMAS, Hematology, General Medicine, medicine.disease, Lymphoma, Radiation therapy, YOUNG-PATIENTS, Oncology, Doxorubicin, Vincristine, Positron emission tomography, Positron-Emission Tomography, Monoclonal, biology.protein, Prednisone, Lymphoma, Large B-Cell, Diffuse, Antibody, Rituximab, business, Diffuse large B-cell lymphoma
Abstract

To the Editor, Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma subtype, accounting for approximately 30% of new cases of non-Hodgkin's lymphoma (NHL) [1]. Despite its a...

Published
2015

2. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study

Author

Enrico Pogliani, Monica Bellei, Maurizio Martelli, Richard W. Tsang, Sergio Cortelazzo, Gianluca Gaidano, Stefano Luminari, Andrea Rossi, Franco Cavalli, Elena Oldani, Armando López-Guillermo, Massimo Federico, Mary Gospodarowicz, Annarita Conconi, Michael Mian, Mario Busetto, Emanuele Zucca, Maria Elena Cabrera, Alessandro Rambaldi, Fausto Rossini, Mian, M, Gaidano, G, Conconi, A, Tsang, R, Gospodarowicz, M, Rambaldi, A, Rossi, A, Oldani, E, Federico, M, Luminari, S, Bellei, M, Pogliani, E, Rossini, F, Cabrera, M, Martelli, M, Lopez Guillermo, A, Busetto, M, Cavalli, F, Zucca, E, and Cortelazzo, S

Subjects
Male, Cancer Research, medicine.medical_treatment, Disease, Gastroenterology, hashimotos-thyroiditis, thyroid, MED/15 - MALATTIE DEL SANGUE, Thyroid Neoplasm, Response rate (survey), Aged, 80 and over, combination chemotherapy, treatment, Thyroid, malignant-lymphoma, Hematology, Middle Aged, Prognosis, Combined Modality Therapy, Survival Rate, localized aggressive lymphoma, medicine.anatomical_structure, Treatment Outcome, Oncology, Female, Lymphoma, Large B-Cell, Diffuse, chop plus radiotherapy, cooperative-oncology-group, elderly-patients, non-hodgkins-lymphoma, prognostic-factors, stage ie, Human, Adult, medicine.medical_specialty, Prognosi, lymphoma, Internal medicine, medicine, Humans, In patient, Combined Treatment Modalities, Thyroid Neoplasms, Aged, Chemotherapy, business.industry, medicine.disease, Surgery, Lymphoma, Radiation therapy, DLBCL, business
Abstract

The impact of different treatment modalities and prognostic factors on the clinical course of primary thyroid diffuse large B-cell lymphoma (PTDLBCL) is still the subject of research. This study was conducted to clarify these clinical aspects of this disorder. The clinical parameters of 48 patients with PTDLBCL at time of diagnosis were comparable to those of previous studies. Patients underwent either radiotherapy (RT) ±° surgery (SX), chemotherapy (CHT) alone or in combination with local treatments (RT or SX), or SX followed by CHT and RT. A 90% complete remission (CR) rate was observed among patients who underwent combined treatment modalities (CTM), compared to 76% among the others. The 5-year progression-free survival differed significantly between both groups (p = 0.028). Poor performance status and advanced age correlated with decreased survival. PTDLBCL is a curable disease prevalent in elderly patients. Combined treatment modalities were able to induce an elevated rate of CR, improving long-term survival in younger patients. However, the outcome in elderly patients still remains unsatisfactory. © 2011 Informa UK, Ltd.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results